Findings

What do systematic reviews say?

82 questions · 83 findings · 15 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 13.3%GRADE not reported 3 · 3.6%Very low 16 · 19.3%Low 20 · 24.1%Moderate 12 · 14.5%High 21 · 25.3%

Repetitive transcranial magnetic stimulation (rTMS) vs sham rTMS

Withdrawals due to adverse events · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 50 participants
GRADE not reported

Intervention not reported

rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 690 participants
Low

Intervention not reported

rhIGF‐I, 0.1 mg/kg/day ‐ change in AALSRS at 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 357 participants
Low

Intervention not reported

rhIGF‐I, 0.1 mg/kg/day ‐ change in SIP after 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
156 participants
Low

Intervention not reported

rhIGF‐I, all doses ‐ injection site pain · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 449 participants
Low

Intervention not reported

rhIGF‐I, all doses ‐ injection site inflammation/reaction · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 779 participants
Low

Intervention not reported

Tracheostomy‐free survival · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 386 participants
High

Intervention not reported

ALSFRS‐R slope Change in ALSFRS‐R / month · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 386 participants
High

Intervention not reported

FVC Slope Change in FVC / month · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 211 participants
High

Any CNTF vs placebo

Deaths · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in deaths compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.07 [0.81, 1.41]
2 studies · 1300 participants
High

Any CNTF vs placebo

Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1300 participants
High

Any CNTF vs placebo

FVC (% predicted) Change from baseline · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1300 participants
High

Changes in quality of life (SIP) change in Sickness Impact Profile (SIP) scores (range from 0 = best health to 100 = worst health). · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
1 study · 503 participants
High

Any CNTF vs placebo

Asthenia · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in asthenia compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.02 [0.81, 1.28]
1 study · 570 participants
High

Any CNTF vs placebo

Nausea · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in nausea compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.35 [0.92, 1.99]
1 study · 570 participants
High

Any CNTF vs placebo

Increased salivation · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in increased salivation compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.08 [0.78, 1.5]
1 study · 570 participants
High

Modafinil vs placebo

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Modafinil vs placebo

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Exercise vs usual care

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Exercise vs usual care

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low